ANDA 206191, held by Inforlife. Metronidazole.
As of Nov 21, 2026, ANDA 206191 (Metronidazole In Plastic Container), held by Inforlife, was first approved by FDA on Feb 25, 2019, with 4 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of Metronidazole Injection and other antibacterial drugs, Metronidazole Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 25, 2019 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Metronidazole In Plastic Container500MG/100ML · injectable;injection | Metronidazole | Rx |
| Dec 3, 2024 | Supplement 16Labeling · Standard review | Approved | None posted |
| Sep 19, 2023 | Supplement 5Labeling · Standard review | Approved | None posted |
| Sep 19, 2023 | Supplement 6Labeling · Standard review | Approved | None posted |
| Sep 19, 2023 | Supplement 12Labeling · Standard review | Approved | None posted |
| Feb 25, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters